Opendata, web and dolomites

ImmUniverse SIGNED

Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ImmUniverse project word cloud

Explore the words cloud of the ImmUniverse project. It provides you a very rough idea of what is the project "ImmUniverse" about.

assays    inform    formed    clinical    methodology    medical    atopic    anticipated    liquid    biopsies    industrialized    realization    fill    disruptive    prerequisites    respective    progression    biomarkers    precision    immuniverse    reduce    employing    diagnosis    disease    compare    improvement    diseases    gap    cross    time    omics    corresponding    treatment    implementing    tissue    combination    transdisciplinary    therapies    colitis    combine    detectable    profiling    circulating    diagnostics    tackle    imid    predictive    severity    interactions    biomarker    recirculating    cohorts    crosstalk    systematically    mechanistic    imids    datasets    unmet    mediated    individual    limitations    tailor    cells    socioeconomic    enormous    countries    immune    invasive    monitoring    ulcerative    outcome    heterogeneity    course    understand    patient    therapy    observational    microenvironment    regard    biopsy    medicine    signatures    burden    signature    monitor    dermatitis    significantly    validated    technologies    hence    prospective    adequately    worldwide   

Project "ImmUniverse" data sheet

The following table provides information about the project.

Coordinator
HUMANITAS UNIVERSITY 

Organization address
address: VIA RITA LEVI MONTALCINI SNC
city: PIEVE EMANUELE
postcode: 20090
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 31˙110˙000 €
 EC max contribution 15˙500˙000 € (50%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2018-15-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HUMANITAS UNIVERSITY IT (PIEVE EMANUELE) coordinator 1˙970˙093.00
2    CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL DE (KIEL) participant 2˙613˙900.00
3    AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH AT (WIEN) participant 2˙133˙236.00
4    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 1˙248˙421.00
5    JOANNEUM RESEARCH FORSCHUNGSGESELLSCHAFT MBH AT (GRAZ) participant 834˙408.00
6    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 740˙000.00
7    UNIVERSITE DU LUXEMBOURG LU (ESCH-SUR-ALZETTE) participant 687˙000.00
8    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 659˙793.00
9    VIB VZW BE (ZWIJNAARDE - GENT) participant 652˙500.00
10    EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH DE (ST INGBERT) participant 626˙062.00
11    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 564˙047.00
12    ISTITUTO SUPERIORE DI SANITA IT (ROMA) participant 504˙988.00
13    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 492˙475.00
14    INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM) SA LU (Esch-sur-Alzette) participant 402˙501.00
15    SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO S ANNA IT (PISA) participant 362˙000.00
16    AARHUS UNIVERSITETSHOSPITAL DK (AARHUS) participant 355˙596.00
17    CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY FR (NANCY CEDEX) participant 340˙783.00
18    AARHUS UNIVERSITET DK (AARHUS C) participant 199˙847.00
19    EUROPEAN FEDERATION OF CROHN'S AND ULCERATIVE COLITIS ASSOCIATIONS BE (BRUXELLES) participant 50˙312.00
20    EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING BE (Brussels) participant 50˙250.00
21    FORUM EUROPEEN DES PATIENTS (FPE) LU (LUXEMBOURG) participant 11˙781.00
22    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
23    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
24    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
25    PFIZER LIMITED UK (SANDWICH) participant 0.00
26    SANOFI-AVENTIS DEUTSCHLAND GMBH DE (FRANKFURT AM MAIN) participant 0.00

Map

 Project objective

Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which currently cannot be adequately anticipated to tailor individual patient management. Hence, mechanistic understanding of this heterogeneity and biomarkers predictive for disease control and therapy response over time are important prerequisites of a future precision medicine in IMIDs. ImmUniverse has been formed as a European transdisciplinary consortium to tackle these unmet needs and to understand the role of the crosstalk between tissue microenvironment and immune cells in disease progression and response to therapy of two different IMIDs: ulcerative colitis and atopic dermatitis. Following this unique cross-disease approach ImmUniverse will fill the gap and the limitations of current studies, which do not systematically compare the complex interactions between recirculating immune cells and the respective tissue microenvironment. The consortium will combine analysis of tissue-derived signatures with “circulating signatures” detectable in liquid biopsies, employing state-of-the-art profiling technologies corresponding to multi-Omics datasets. The project will also bring diagnostics in IMID to a new level by implementing disruptive non-invasive liquid-biopsy methodology in combination with novel, validated circulating biomarker assays which are expected to improve diagnosis, inform early in the clinical course on disease severity and progression and enable treatment response monitoring. The identified signature will be validated to monitor state/progression and response to therapy in prospective observational cohorts. Realization of these objectives will result in improvement of patient management, lead to increased patient well-being and will significantly reduce the socioeconomic burden of these diseases.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNIVERSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNIVERSE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

VITAL (2019)

Vaccines and Infectious Diseases in the Ageing PopuLation

Read More  

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More